| A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma P van der Bruggen, C Traversari, P Chomez, C Lurquin, E De Plaen, ... Science 254 (5038), 1643-1647, 1991 | 4782 | 1991 |
| Tumor antigens recognized by T lymphocytes P van der Bruggen, A Van Pel Annu. Rev, Immunol 12, 337-65, 1994 | 1679 | 1994 |
| Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy PG Coulie, BJ Van den Eynde, P Van Der Bruggen, T Boon Nature Reviews Cancer 14 (2), 135-146, 2014 | 1353 | 2014 |
| Human tumor antigens recognized by T lymphocytes. T Boon, P van der Bruggen The Journal of experimental medicine 183 (3), 725-729, 1996 | 1190 | 1996 |
| Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 M Marchand, N Van Baren, P Weynants, V Brichard, B Dréno, MH Tessier, ... International journal of cancer 80 (2), 219-230, 1999 | 1126 | 1999 |
| Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. B Gaugler, B Van den Eynde, P van der Bruggen, P Romero, JJ Gaforio, ... The Journal of experimental medicine 179 (3), 921-930, 1994 | 998 | 1994 |
| Structure, chromosomal localization, and expression of 12 genes of the MAGE family E De Plaen, C Traversari, JJ Gaforio, JP Szikora, C De Smet, F Brasseur, ... Immunogenetics 40, 360-369, 1994 | 990 | 1994 |
| A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. C Traversari, P van der Bruggen, IF Luescher, C Lurquin, P Chomez, ... The Journal of experimental medicine 176 (5), 1453-1457, 1992 | 872 | 1992 |
| T cell defined tumor antigens BJ Van den Eynde, P Van Der Bruggen Current opinion in immunology 9 (5), 684-693, 1997 | 813 | 1997 |
| BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes P Boël, C Wildmann, ML Sensi, R Brasseur, JC Renauld, P Coulie, ... Immunity 2 (2), 167-175, 1995 | 812 | 1995 |
| Tumor‐specific shared antigenic peptides recognized by human T cells P Van Der Bruggen, Y Zhang, P Chaux, V Stroobant, C Panichelli, ... Immunological reviews 188 (1), 51-64, 2002 | 594 | 2002 |
| A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 P van der Bruggen, J Bastin, T Gajewski, PG Coulie, P Boël, C De Smet, ... European journal of immunology 24 (12), 3038-3043, 1994 | 470 | 1994 |
| An antigenic peptide produced by peptide splicing in the proteasome N Vigneron, V Stroobant, J Chapiro, A Ooms, G Degiovanni, S Morel, ... Science 304 (5670), 587-590, 2004 | 431 | 2004 |
| A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma S Mandruzzato, F Brasseur, G Andry, T Boon, P Bruggen The Journal of experimental medicine 186 (5), 785-793, 1997 | 424 | 1997 |
| Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes P Chaux, V Vantomme, V Stroobant, K Thielemans, J Corthals, R Luiten, ... The Journal of experimental medicine 189 (5), 767-778, 1999 | 333 | 1999 |
| Genes coding for tumor antigens recognized by cytolytic T lymphocytes. A Pel, P Bruggen, PG Coulie, VG Brichard, B Lethé, B Eynde, ... | 297 | 1995 |
| Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601 PVD Bruggen, JP Szikora, P Boël, C Wildmann, M Somville, M Sensi, ... European journal of immunology 24 (9), 2134-2140, 1994 | 296 | 1994 |
| Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood PR Dunbar, GS Ogg, J Chen, N Rust, P van der Bruggen, V Cerundolo Current Biology 8 (7), 413-416, 1998 | 291 | 1998 |
| Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients A Bonehill, AMT Van Nuffel, J Corthals, S Tuyaerts, C Heirman, ... Clinical Cancer Research 15 (10), 3366-3375, 2009 | 281 | 2009 |
| Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3 YC Lu, LL Parker, T Lu, Z Zheng, MA Toomey, DE White, X Yao, YF Li, ... Journal of Clinical Oncology 35 (29), 3322-3329, 2017 | 277 | 2017 |
